Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Fung

Vascular & Interventional Radiology Houston, TX Medical Doctor

NPI 1497012199 CMS profile 2859260

6431 Fannin, Msb 2.132, Houston, TX 77030

Open in the dashboard

General payments

$16,449

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Fung of Houston, TX is reported in the CMS Open Payments database as having received $16,449 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,477 12
2024 General $3,348 30
2023 General $5,353 30
2022 General $2,575 18
2021 General $769 14
2020 General $838 18
2019 General $2,089 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Fung
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Daniel Fung were reported at $1,477. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Daniel Fung Vascular & Interventional Radiology median Middle half National median
2019 $2,089 $422 $125–$1,555 $163
2020 $838 $200 $68–$652 $114
2021 $769 $280 $99–$866 $132
2022 $2,575 $433 $137–$1,497 $149
2023 $5,353 $506 $152–$2,019 $160
2024 $3,348 $556 $175–$1,930 $164
2025 $1,477 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $6,137 26 payments
  2. Boston Scientific Corporation $5,697 55 payments
  3. Biocompatibles, Inc. $1,009 11 payments
  4. Medtronic USA, Inc. $552 8 payments
  5. Terumo Medical Corporation $483 2 payments
  6. Sirtex Medical Inc $395 2 payments
  7. Inari Medical, Inc. $367 7 payments
  8. Bard Peripheral Vascular, Inc. $341 8 payments
  9. Medtronic Vascular, Inc. $304 7 payments
  10. Histosonics, Inc. $302 1 payment
  11. Other $861 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,062 134 payments
  2. Travel and Lodging $4,637 14 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
  4. Consulting Fee $350 1 payment
Products named General payments · program years 2019–2025
  1. RUBY Coil $4,990 13 payments
  2. General - Therapies $1,898 6 payments
  3. THERASPHERE-BIO $990 10 payments
  4. TheraSphere Y90 Glass Microspheres 10 GBq $954 11 payments
  5. Indigo System $766 9 payments
  6. KYPHON Balloon Kyphoplasty $552 8 payments
  7. NAVICROSS $483 2 payments
  8. THERASPHERE $438 6 payments
  9. EMBOLD Fibered $436 5 payments
  10. CT THROMBECTOMY SYSTEM KIT $367 7 payments
  11. Other $4,153 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Diagnostic Radiology: 24

Drug cost

$565

Median for Diagnostic Radiology: $190

Branded share of claims

31.4%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 16 $355
Ciprofloxacin Hcl Generic 23 $125
Methylprednisolone Generic 12 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 156 billing codes

Paid by Medicare

$54,818

Medicare's payments for the services billed

Medicare patients

313

Average age 75

Services billed

831

160 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 40%
Chronic kidney disease 38%
Ischemic heart disease 36%
Heart failure 30%
COPD 30%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record